CliffBio
small molecule

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

Loss of exclusivity—loss of exclusivity
CompanyTris. →See this company's full patent-cliff portfolio

Drug detail

Brand nameHYDROCODONE BITARTRATE AND ACETAMINOPHEN
Active ingredientACETAMINOPHEN; HYDROCODONE BITARTRATE
Strength300MG/15ML;10MG/15ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2021
Marketing statusDISCN

More from Tris.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

HYDROCODONE BITARTRATE AND ACETAMINOPHEN patent cliff — loss of exclusivity — | CliffBio